Literature DB >> 22720229

A matched couple: Combining kinase inhibitors with immunotherapy for cancer treatment.

Qun Jiang1, Jonathan M Weiss, Robert H Wiltrout.   

Abstract

Small-molecule kinase inhibitors targeting oncogenic signaling pathways have been explored as cancer therapeutic agents due to their strong anti-tumor activity and manageable toxicity. Accumulating evidence shows that many kinase inhibitors also profoundly modulate immune cell functions, suggesting they may be promising candidates for combination with immunotherapeutic agents for the improved treatment of cancer.

Entities:  

Year:  2012        PMID： 22720229      PMCID： PMC3376952          DOI： 10.4161/onci.1.1.18036

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  CCL2 blockade augments cancer immunotherapy.

Authors:  Zvi G Fridlender; George Buchlis; Veena Kapoor; Guanjun Cheng; Jing Sun; Sunil Singhal; M Cecilia Crisanti; Cecilia Crisanti; Liang-Chuan S Wang; Daniel Heitjan; Linda A Snyder; Steven M Albelda
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

2.  Drosophila Ras/MAPK signalling regulates innate immune responses in immune and intestinal stem cells.

Authors:  Anan Ragab; Tina Buechling; Viola Gesellchen; Kerstin Spirohn; Anna-Lisa Boettcher; Michael Boutros
Journal:  EMBO J       Date:  2011-02-04       Impact factor: 11.598

3.  mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.

Authors:  Qun Jiang; Jonathan M Weiss; Timothy Back; Tim Chan; John R Ortaldo; Sylvie Guichard; Robert H Wiltrout
Journal:  Cancer Res       Date:  2011-05-03       Impact factor: 12.701

Review 4.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

5.  Activation of Akt as a mechanism for tumor immune evasion.

Authors:  Kyung Hee Noh; Tae Heung Kang; Jin Hee Kim; Sara I Pai; Ken Y Lin; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

6.  Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma.

Authors:  Fang Zhao; Christine Falk; Wolfram Osen; Masashi Kato; Dirk Schadendorf; Viktor Umansky
Journal:  Clin Cancer Res       Date:  2009-06-23       Impact factor: 12.531

7.  Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.

Authors:  Y Wang; X-Y Wang; J R Subjeck; P A Shrikant; H L Kim
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

8.  The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function.

Authors:  Kai Yang; Geoffrey Neale; Douglas R Green; Weifeng He; Hongbo Chi
Journal:  Nat Immunol       Date:  2011-07-17       Impact factor: 25.606

9.  Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production.

Authors:  Tai-An Chen; Jui-Ling Wang; Shao-Wen Hung; Chiao-Li Chu; Yung-Chih Cheng; Shu-Mei Liang
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.